Impact of low-level pretransplant donor-specific antibodies detected by the Luminex platform on acute rejection and long-term graft survival

Table 1 Demographic and clinical parameters of the study population

Parameter	n = 78
Age of recipients (years)	29.57 ± 10.11
Recipient gender
Males	49 (62.8)
Females	29 (37.2)
Age of donors (years)	34.53 ± 9.09
Donor gender
Males	46 (59.0)
Females	32 (51.0)
Donor relation
Siblings	46 (58.9)
Parents	14 (17.9)
Spouses	17 (21.8)
Offspring	1 (1.3)
HLA mismatches
1-2	21 (27.0)
3-4	37 (47.4)
5-6	20 (25.6)
Duration of hemodialysis (months)	14.01 ± 15.48
End-stage kidney disease cause
Unknown	48 (61.5)
Chronic glomerulonephritis	20 (25.6)
Stone disease	5 (6.4)
Bladder outlet obstruction and neurogenic bladder	3 (3.8)

Data are presented as n (%) or mean ± SD. HLA: Human leucocyte antigen.

Table 2 Donor-specific antibodies against human leukocyte antigen class positivity and rejection episodes

Parameter	Mean DSA MFI
DSA Class I, n = 36 (46.2%)	3286.58 ± 4530.50; Range: 933-9994
DSA Class II, n = 35 (44.8%)	3207.47 ± 4219.00; Range: 1041-9383
DSA Class I and II, n = 7 (8.9%)	Class I = 3245.00 ± 2117.00; Range: 5515-6518
	Class II = 2101.00 ± 959.00; Range: 2336- 3610
In rejection (n = 8)
Class I, n = 2 (25.0%)	Median = 4994 (IQR = 3922-4994)
Class II, n = 6 (75.0%)	Median = 2718 (IQR = 1221-5173)
In no rejection (n = 63)
Class I, n = 34 (48.5%)	Median = 2481 (IQR = 1732-4136)
Class II, n = 29 (41.4%)	Median = 3088 (IQR = 1479- 5249)

DSA: Donor-specific antibodies; MFI: Mean fluorescence index; IQR: Interquartile range.